Ovarian Epithelial Cancer clinical trials

Explore recruiting ovarian epithelial cancer clinical trials.

Recruiting ovarian epithelial cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ovarian Epithelial Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)

Germany, Czechia, Hungary, Spain, Italy, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

NIRAPK : Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer

France

Therapeutic use (Phase IV) EU CTIS Study details

Sentinel node detection with 99Tc albumin nanocolloid and indocianine green (ICG) in patients with epithelial ovarian cancer in early stages. Pilot study.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

MATAO MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Ireland, Greece, Czechia, France, Sweden, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Spain, Czechia, Germany, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Ovarian Epithelial Cancer trials by city

Ovarian Epithelial Cancer in Toronto Ovarian Epithelial Cancer in Vancouver Ovarian Epithelial Cancer in Montreal Ovarian Epithelial Cancer in Calgary Ovarian Epithelial Cancer in Edmonton Ovarian Epithelial Cancer in Ottawa Ovarian Epithelial Cancer in Winnipeg Ovarian Epithelial Cancer in Quebec City Ovarian Epithelial Cancer in Hamilton Ovarian Epithelial Cancer in Kitchener Ovarian Epithelial Cancer in London Ovarian Epithelial Cancer in Halifax Ovarian Epithelial Cancer in New York Ovarian Epithelial Cancer in Los Angeles Ovarian Epithelial Cancer in Chicago Ovarian Epithelial Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease